Assuntos
Aprovação de Drogas/economia , Indústria Farmacêutica/economia , Doenças Negligenciadas/tratamento farmacológico , Desenvolvimento de Programas/economia , Doenças Raras/tratamento farmacológico , Anticorpos Monoclonais/economia , Antimaláricos/economia , Antineoplásicos/economia , Antiprotozoários/economia , Antituberculosos/economia , Combinação Arteméter e Lumefantrina , Artemisininas/economia , Ácido Cólico/economia , Condroitina Sulfatases/economia , Diarilquinolinas/economia , Aprovação de Drogas/legislação & jurisprudência , Aprovação de Drogas/métodos , Combinação de Medicamentos , Indústria Farmacêutica/legislação & jurisprudência , Etanolaminas/economia , Fluorenos/economia , Humanos , Fosforilcolina/análogos & derivados , Fosforilcolina/economia , Estados Unidos , United States Food and Drug AdministrationRESUMO
Hematogenous dissemination is thought to be a late event in cancer progression. We recently showed in a genetic model of pancreatic ductal adenocarcinoma that pancreas cells can be detected in the bloodstream before tumor formation. To confirm these findings in humans, we used microfluidic geometrically enhanced differential immunocapture to detect circulating pancreas epithelial cells in patient blood samples. We captured more than 3 circulating pancreas epithelial cells/mL in 7 of 21 (33%) patients with cystic lesions and no clinical diagnosis of cancer (Sendai criteria negative), 8 of 11 (73%) with pancreatic ductal adenocarcinoma, and in 0 of 19 patients without cysts or cancer (controls). These findings indicate that cancer cells are present in the circulation of patients before tumors are detected, which might be used in risk assessment.
Assuntos
Células Epiteliais/patologia , Células Neoplásicas Circulantes/patologia , Pâncreas/patologia , Cisto Pancreático/diagnóstico , Cisto Pancreático/patologia , Adenocarcinoma/diagnóstico , Adenocarcinoma/patologia , Adulto , Idoso , Idoso de 80 Anos ou mais , Carcinoma Ductal Pancreático/diagnóstico , Carcinoma Ductal Pancreático/patologia , Estudos de Casos e Controles , Feminino , Imunofluorescência , Humanos , Masculino , Técnicas Analíticas Microfluídicas , Pessoa de Meia-Idade , Projetos Piloto , Estudos Prospectivos , Medição de RiscoRESUMO
Cellular reprogramming-the ability to interconvert distinct cell types with defined factors-is transforming the field of regenerative medicine. However, this phenomenon has rarely been observed in vivo without exogenous factors. Here, we report that activation of Notch, a signaling pathway that mediates lineage segregation during liver development, is sufficient to reprogram hepatocytes into biliary epithelial cells (BECs). Moreover, using lineage tracing, we show that hepatocytes undergo widespread hepatocyte-to-BEC reprogramming following injuries that provoke a biliary response, a process requiring Notch. These results provide direct evidence that mammalian regeneration prompts extensive and dramatic changes in cellular identity under injury conditions.
